Five Observations From Successful Oncology ‘First Launches’

Posted by Ben Hohn on Aug 14, 2017 10:29:32 AM

Nicholas Martinez and Cody Powers co-wrote this blog post with Ben Hohn.

The stakes are high when preparing to launch a new drug, but for a biopharmaceutical company staring down its first-ever oncology launch, the stakes are even higher. Drug launches in the oncology space have grown increasingly competitive and occur more frequently than in any other therapeutic category. And of the 202 novel drugs approved by the FDA from 2011 to 2016, five were oncology drugs launched in the U.S. by publicly traded newcomers—so-called “first launches.”  


>
Read More

Five Reasons That Positioning Matters in Oncology

Posted by Malik Kaman on May 6, 2016 8:00:00 AM

Many of us in the biopharmaceutical industry marvel at the tidal wave of new treatment options in oncology. This trend should only accelerate with literally hundreds of unique medicines in phase two and phase three trials across a variety of tumor types. But what are the commercial implications of this trend?


>
Read More